Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Imugene ( (AU:IMU) ).
Imugene Limited has applied for quotation on the ASX of 31,220,668 new ordinary fully paid shares, with an issue date of 30 April 2026, under its existing ticker IMU. The newly issued securities form part of a previously announced transaction, indicating an expansion of the company’s share capital that may support ongoing corporate or development activities and modestly dilute existing shareholders while potentially strengthening its funding base.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australian biotechnology company listed on the ASX under the code IMU. The company operates in the life sciences sector, focusing on the development of immunotherapy-based treatments, and raises capital through the issuance and quotation of ordinary fully paid shares on the Australian market.
Average Trading Volume: 1,591,716
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$48.37M
See more data about IMU stock on TipRanks’ Stock Analysis page.